Company intelligence / Profile preview
SQY Therapeutics
Guyancourt, Île-de-France / Yvelines, Francesqy-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
SQY Therapeutics has developed a next-generation tricyclo-DNA antisense oligonucleotide platform. Its lead candidate targets exon 51 skipping in the dystrophin gene to treat Duchenne Muscular Dystrophy and is advancing toward or entering Phase 1/2a trials. The company’s tcDNA ASOs show improved RNA binding affinity and tissue distribution compared to earlier generations, with potential applications across multiple genetic diseases. No published clinical results are available yet.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Antisense oligonucleotideTricyclo-DNA class (tcDNA) antisense oligonucleotide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Association Monégasque contre les Myopathies (AMM)Duchenne Parent Project France
Beyond the preview
Go deeper on SQY Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SQY Therapeutics.